Prot #MK-3475-C11-01: Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)

Project: Research project

Project Details

StatusActive
Effective start/end date2/24/222/24/25

Funding

  • Merck Sharp & Dohme Corporation ((OE) Prot #MK-3475-C11-01)